4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-20-047620
Chief R&D Officer sold 26,200 shares at $19.67 ($515,354)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2020-08-17 | Sale | −26,200 | $19.67 | $515,354 | 296,315 | D: show line 1 in the form |
| Open-market sales · 26,200 sh · avg $19.67 · $515,354 | |||||||
Loading xslF345X03/doc4.xml…